AcouSort AB (publ) (ACOU.ST)
SEK 3.75
(0.81%)
SEK 3.75
(0.81%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -16.7 Million SEK | -30.05% |
| 2022 | -12.85 Million SEK | -12.85% |
| 2021 | -11.45 Million SEK | -49.0% |
| 2020 | -7.71 Million SEK | 20.31% |
| 2019 | -9.58 Million SEK | -7.53% |
| 2018 | -8.91 Million SEK | -47.19% |
| 2017 | -6.05 Million SEK | -841.84% |
| 2016 | - SEK | -133.65% |
| 2015 | -279 Thousand SEK | -326.58% |
| 2014 | 121.45 Thousand SEK | 295.43% |
| 2013 | -62.14 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.61 Million SEK | -26.07% |
| 2024 Q1 | -5.85 Million SEK | 41.84% |
| 2023 Q2 | -3.04 Million SEK | -8.49% |
| 2023 Q4 | -7.25 Million SEK | -83.07% |
| 2023 FY | - SEK | -69.11% |
| 2023 Q3 | -3.96 Million SEK | -30.31% |
| 2023 Q1 | -2.8 Million SEK | -6.45% |
| 2022 FY | - SEK | -12.85% |
| 2022 Q4 | -2.63 Million SEK | 32.69% |
| 2022 Q3 | -3.91 Million SEK | -1.37% |
| 2022 Q2 | -3.86 Million SEK | -58.26% |
| 2022 Q1 | -2.43 Million SEK | 23.81% |
| 2021 Q4 | -3.2 Million SEK | 1.45% |
| 2021 Q1 | -1.52 Million SEK | 51.4% |
| 2021 Q2 | -3.24 Million SEK | -112.85% |
| 2021 Q3 | -3.24 Million SEK | -0.06% |
| 2021 FY | - SEK | -49.0% |
| 2020 Q3 | -2.18 Million SEK | -66.59% |
| 2020 FY | - SEK | 20.31% |
| 2020 Q1 | -998 Thousand SEK | 68.5% |
| 2020 Q2 | -1.31 Million SEK | -31.66% |
| 2020 Q4 | -3.13 Million SEK | -43.35% |
| 2019 Q2 | -3.11 Million SEK | -97.71% |
| 2019 FY | - SEK | -7.53% |
| 2019 Q4 | -3.16 Million SEK | -83.44% |
| 2019 Q3 | -1.72 Million SEK | 44.54% |
| 2019 Q1 | -1.57 Million SEK | 45.97% |
| 2018 Q1 | -2.25 Million SEK | -4.16% |
| 2018 Q4 | -2.91 Million SEK | -39.47% |
| 2018 FY | - SEK | -47.19% |
| 2018 Q3 | -2.09 Million SEK | -26.06% |
| 2018 Q2 | -1.65 Million SEK | 26.34% |
| 2017 Q3 | -1.28 Million SEK | 26.74% |
| 2017 FY | - SEK | -841.84% |
| 2017 Q1 | -864 Thousand SEK | -24.5% |
| 2017 Q2 | -1.75 Million SEK | -102.55% |
| 2017 Q4 | -2.16 Million SEK | -68.56% |
| 2016 Q3 | 134 Thousand SEK | 191.3% |
| 2016 FY | - SEK | -133.65% |
| 2016 Q1 | -117 Thousand SEK | 45.63% |
| 2016 Q4 | -694 Thousand SEK | -617.91% |
| 2016 Q2 | 46 Thousand SEK | 139.32% |
| 2015 Q4 | -215.2 Thousand SEK | -239.74% |
| 2015 Q3 | 154 Thousand SEK | 0.0% |
| 2015 FY | - SEK | -326.58% |
| 2014 FY | - SEK | 295.43% |
| 2013 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 95.459% |
| Active Biotech AB (publ) | -43.88 Million SEK | 61.941% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 39869.995% |
| Amniotics AB (publ) | -27.14 Million SEK | 38.463% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -17.486% |
| BioArctic AB (publ) | 275.38 Million SEK | 106.065% |
| Camurus AB (publ) | 562.54 Million SEK | 102.969% |
| Cantargia AB (publ) | -284.31 Million SEK | 94.125% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 14.689% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 2.233% |
| Genovis AB (publ.) | 64.57 Million SEK | 125.867% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 85.464% |
| Mendus AB (publ) | -97.84 Million SEK | 82.929% |
| Kancera AB (publ) | -61.88 Million SEK | 73.011% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 37.636% |
| LIDDS AB (publ) | -39.67 Million SEK | 57.895% |
| Lipum AB (publ) | -37.11 Million SEK | 55.001% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -37.996% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 153.187% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 835250.0% |
| NextCell Pharma AB | -40.98 Million SEK | 59.246% |
| OncoZenge AB (publ) | 7.26 Million SEK | 329.879% |
| Saniona AB (publ) | -69.69 Million SEK | 76.034% |
| Simris Alg AB (publ) | -22.36 Million SEK | 25.31% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 94.739% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 94.078% |
| Xintela AB (publ) | -53.47 Million SEK | 68.763% |
| Ziccum AB (publ) | -20.34 Million SEK | 17.889% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 54.886% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 90.164% |
| CombiGene AB (publ) | -35.33 Million SEK | 52.731% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 88.141% |
| Intervacc AB (publ) | -68.98 Million SEK | 75.786% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 92.971% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -703.029% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -24.362% |
| Corline Biomedical AB | -1.69 Million SEK | -887.759% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 90.363% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 69.523% |
| Aptahem AB (publ) | -10 Million SEK | -66.876% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 244.627% |
| Fluicell AB (publ) | -25.91 Million SEK | 35.544% |
| Biovica International AB (publ) | -119.5 Million SEK | 86.023% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 60.442% |
| Abliva AB (publ) | -93.6 Million SEK | 82.156% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 94.766% |
| 2cureX AB (publ) | -35.13 Million SEK | 52.462% |
| I-Tech AB | 30.34 Million SEK | 155.044% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 97.662% |
| Cyxone AB (publ) | -20.41 Million SEK | 18.179% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 83.697% |
| Biosergen AB | 228 Thousand SEK | 7425.877% |
| Nanologica AB (publ) | -62.11 Million SEK | 73.111% |
| SynAct Pharma AB | -222.7 Million SEK | 92.5% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 61.918% |
| BioInvent International AB (publ) | -312.7 Million SEK | 94.659% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 5498.286% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 92.789% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -89.538% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 84.614% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -45.636% |